VENTO, Antonio
 Distribuzione geografica
Continente #
NA - Nord America 599
EU - Europa 598
AS - Asia 163
Totale 1.360
Nazione #
US - Stati Uniti d'America 590
IE - Irlanda 188
SE - Svezia 174
IT - Italia 97
SG - Singapore 65
CN - Cina 57
PL - Polonia 46
DE - Germania 36
IN - India 26
FR - Francia 14
FI - Finlandia 12
GB - Regno Unito 12
BE - Belgio 9
CA - Canada 9
VN - Vietnam 6
LT - Lituania 5
ES - Italia 3
ID - Indonesia 3
IR - Iran 3
HK - Hong Kong 2
AT - Austria 1
TW - Taiwan 1
UA - Ucraina 1
Totale 1.360
Città #
Chandler 212
Dublin 186
Nyköping 125
Singapore 55
Ashburn 47
Warsaw 46
Messina 42
Princeton 34
Medford 25
Bremen 24
Des Moines 20
Dearborn 13
Ann Arbor 12
Helsinki 12
Hyderabad 12
Beijing 11
Rome 11
Brussels 9
Jacksonville 9
Jinan 9
Mumbai 9
Munich 9
Boardman 7
Los Angeles 7
Nanjing 7
Dong Ket 6
Hangzhou 5
Ottawa 5
Tianjin 5
Nanchang 4
Redwood City 4
Seattle 4
Waverly Hall 4
Florence 3
Jakarta 3
Mislata 3
Pune 3
Santa Domenica 3
Toronto 3
Torregrotta 3
Wilmington 3
Augusta 2
Fiumefreddo Di Sicilia 2
Frankfurt am Main 2
Hong Kong 2
London 2
Padova 2
Pozzo Di Gotto 2
Taizhou 2
Berlin 1
Cambridge 1
Castelnuovo Rangone 1
Castelvetrano 1
Changsha 1
Chengdu 1
Clifton 1
Duncan 1
Edinburgh 1
Fairfield 1
Fuzhou 1
Houston 1
Lanzhou 1
Leawood 1
Maple Ridge 1
Monserrato 1
Ningbo 1
Palermo 1
Pescara 1
Qingdao 1
San Francisco 1
San Mateo 1
Santa Teresa Di Riva 1
Shenyang 1
Shenzhen 1
Taichung 1
Taiyuan 1
The Dalles 1
Vienna 1
Vittoria 1
Washington 1
Wuhan 1
Zhengzhou 1
Totale 1.063
Nome #
PRRT Retreatments: Renal Function Evaluation 91
Prognostic Validity of Dual Tracer PET/CT in the PRRT Enrollment of GEP-NET Patients 82
Peptide Receptor Radionuclide Therapy and Somatostatin 'cold' Analogues Therapy in the Treatment of GEP-NET Patients: Our Center’ Experience 77
Braf V600E and 99m-TC MIBI scintigraphy are usefull diagnostic tools in identifying metastatic differentiated thyroid cancer patients refractory to radioiodine therapy. 72
Complete Response in a Pancreatic Nen with Liver Metastasis after PRRT in association with Lanreotide Autogel/depot: Design of the Prelude Study 69
Dual Time-Point FET-PET/CT in Glioma Patients: a Single-Centre Preliminary Experience 66
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience 62
Renal Function Evaluation in PRRT Retreatments 62
A Single Centre Experience with 223-Radium-Dichloride ((RaCl2)-Ra-223) Therapy 60
Complete response in a pancreatic NEN with liver metastasis after PRRT in association with lanreotide autogel/depot 58
Combined BRAFV600Eanalysis and99mTc-MIBI scintigraphy can be a useful diagnostic tool in differentiated thyroid cancer patients with incomplete bio-chemical response to first radioiodine therapy (RAIT): a pilot investigation 57
Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients 57
Comparing radioiodine abdominal absorbed dose in differentiated thyroid cancer patients undergone thyroid remnant ablation in either levo-thyroxine withdrawal or after rhtsh stimulation 54
Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study 53
One week of levofloxacin plus dexamethasone eye drops for cataract surgery: an innovative and rational therapeutic strategy 52
Peptide receptor radionuclide therapy (PRRT) in patients with giant aggressive pituitary tumors: experience of an Italian referral center and review of literature 48
Artifcial intelligence applications in SSTR targeted PET/CT images: prediction of response assessment in GEP-NETs undergoing PRRT with [177Lu]DOTATOC 48
PRRT retreatments: renal function evaluation 47
Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging 47
The utility of dual time-point FET-PET/CT in recurrence assessment of glioma patients 45
Peptide Receptor Radionuclide Therapy of Pulmonary Neuroendocrine Neoplasms: a Single-Centre Experience 38
The additional value of 18F-FDG PET and MRI in patients with glioma: A review of the literature from 2015 to 2020 38
Artificial intelligence applications in 68Ga-DOTA PETICT images: Prediction of response assessment in GEP-NETs undergoing PRRT with 177Lu-DOTATOC 37
Correction to: Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging 27
Undetectable or low (< 1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients 26
null 23
Response prediction to PRRT in progressing and metastatic GEP-NET undergoing restaging 68Ga-DOTA PETICT: A preliminary multicenter radiomics study 21
Choline PET/CT features to predict survival outcome in high-risk prostate cancer restaging: a preliminary machine-learning radiomics study 3
Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature 2
Prostate-Specific Membrane Antigen Positron Emission Tomography Oncological Applications beyond Prostate Cancer in Comparison to Other Radiopharmaceuticals 1
PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score 1
Totale 1.424
Categoria #
all - tutte 8.000
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.000


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202054 0 0 0 0 0 11 5 4 2 11 4 17
2020/2021173 12 5 45 6 20 12 12 14 18 11 9 9
2021/2022236 1 13 2 10 20 1 21 21 3 27 22 95
2022/2023652 57 93 28 61 48 60 8 48 229 5 12 3
2023/2024153 13 16 7 10 18 24 9 10 0 13 13 20
2024/2025138 10 24 17 34 53 0 0 0 0 0 0 0
Totale 1.424